Research Institute for Biomolecule Control (RIBC)
History of Establishment
Goal
To explore the life phenomena of biomolecules at a multi-scale level
June 2015
Discussions on establishing the Biomedical Institute for
Convergence at SKKU (proposal) began
December 2015
Establishment of the Biomedical Institute for
Convergence at SKKU (proposal) was finalized
August 2016
The Biomedical Institute for Convergence at SKKU (BICS)
held an international symposium
September 2016
Establishment of the Biomedical Institute for Convergence at SKKU (BICS)
was approved (Director: Prof. Kacunori Kataoka)
February 2017
Establishment of the Research Institute for Biomolecule Control (RIBC)
under the Biomedical Institute for Convergence at SKKU (BICS)
March 2017
Establishment of state-of-the-art infrastructure
and research infrastructure plans finalized
Specialization Plan
Characterized as a specialized research institute for the development, efficacy, and molecular mechanism studies of biomolecules
Biomolecular control and multiscale BioPhenome information acquisition
Utilization/industrialization of biomolecules (Accelerating the Development of Biobetters and Innovative New Drugs)
Hompage: https://swb.skku.edu/ribc/index.do
The final goal
Establishing a spatio-temporal life-form technology (ST-Biophenomics) that can create high added value in the biopharmaceutical industry and transform the R&D paradigm
A step-by-step goal
